Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 347

1.

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.

Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, Lachmann HJ, Quarta C, Fontana M, Gillmore JD, Whelan C, Hawkins PN, Wechalekar AD.

Blood. 2019 Oct 2. pii: blood.2019000834. doi: 10.1182/blood.2019000834. [Epub ahead of print]

PMID:
31578202
2.

Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities.

Orini M, Graham AJ, Martinez-Naharro A, Andrews CM, de Marvao A, Statton B, Cook SA, O'Regan DP, Hawkins PN, Rudy Y, Fontana M, Lambiase PD.

J Am Heart Assoc. 2019 Sep 17;8(18):e012097. doi: 10.1161/JAHA.119.012097. Epub 2019 Sep 8.

3.

A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom.

Sharpley FA, Petrie A, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Fontana M, Martinez-Naharro A, Quarta C, Hawkins PN, Wechalekar AD.

Br J Haematol. 2019 Aug 13. doi: 10.1111/bjh.16143. [Epub ahead of print]

PMID:
31410841
4.

Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.

Sharpley FA, Fontana M, Martinez-Naharro A, Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Hawkins PN, Wechalekar AD.

Haematologica. 2019 Aug 8. pii: haematol.2019.217695. doi: 10.3324/haematol.2019.217695. [Epub ahead of print]

5.

Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.

Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Yong K, Rabin N, Popat R, Kyriakou C, Worthington S, Sharpley F, Smith M, Shah R, Cheesman S, Hawkins PN, Wechalekar AD.

Br J Haematol. 2019 Aug 6. doi: 10.1111/bjh.16122. [Epub ahead of print]

PMID:
31388995
6.

British kindred with dominant FMF associated with high incidence of AA amyloidosis caused by novel MEFV variant, and a review of the literature.

Rowczenio DM, Youngstein T, Trojer H, Omoyinmi E, Baginska A, Brogan P, Papadopoulou C, Rezk T, Hawkins PN, Lachmann HJ.

Rheumatology (Oxford). 2019 Aug 5. pii: kez334. doi: 10.1093/rheumatology/kez334. [Epub ahead of print]

PMID:
31384939
7.

Proteomic Analysis for the Diagnosis of Fibrinogen Aα-chain Amyloidosis.

Taylor GW, Gilbertson JA, Sayed R, Blanco A, Rendell NB, Rowczenio D, Rezk T, Mangione PP, Canetti D, Bass P, Hawkins PN, Gillmore JD.

Kidney Int Rep. 2019 Apr 15;4(7):977-986. doi: 10.1016/j.ekir.2019.04.007. eCollection 2019 Jul.

8.

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome.

Elmi AA, Wynne K, Cheng IL, Eleftheriou D, Lachmann HJ, Hawkins PN, Brogan P.

Pediatr Rheumatol Online J. 2019 Jul 8;17(1):36. doi: 10.1186/s12969-019-0335-4.

9.

Exploratory Study of MYD88 L265P, Rare NLRP3 Variants, and Clonal Hematopoiesis Prevalence in Patients With Schnitzler Syndrome.

Pathak S, Rowczenio DM, Owen RG, Doody GM, Newton DJ, Taylor C, Taylor J, Cargo C, Hawkins PN, Krause K, Lachmann HJ, Savic S.

Arthritis Rheumatol. 2019 Jul 3. doi: 10.1002/art.41030. [Epub ahead of print]

PMID:
31268627
10.

Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis.

Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, Gritti M, Quarta C, Knight DS, Wechalekar AD, Lachmann HJ, Perlini S, Pontone G, Moon JC, Kellman P, Gillmore JD, Hawkins PN, Fontana M.

JACC Cardiovasc Imaging. 2019 Jun 7. pii: S1936-878X(19)30433-4. doi: 10.1016/j.jcmg.2019.03.026. [Epub ahead of print]

PMID:
31202744
11.

The UK National Amyloidosis Centre.

Hawkins PN, Fontana M, Gillmore JD.

Eur Heart J. 2019 Jun 1;40(21):1661-1664. doi: 10.1093/eurheartj/ehz346. No abstract available.

PMID:
31152551
12.

Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.

Rezk T, Lachmann HJ, Fontana M, Naharro AM, Sachchithanantham S, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Hawkins PN, Gillmore JD.

Br J Haematol. 2019 Aug;186(3):460-470. doi: 10.1111/bjh.15955. Epub 2019 May 24.

PMID:
31124579
13.

Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.

Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD.

Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21. Erratum in: Circulation. 2019 Jul 30;140(5):e185.

PMID:
31109193
14.

High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis.

Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC, Garcia-Pavia P, Gillmore JD, Hawkins PN, Fontana M.

J Am Coll Cardiol. 2019 Apr 9;73(13):1733-1734. doi: 10.1016/j.jacc.2019.01.035. No abstract available.

PMID:
30947929
15.

Spinal Stenosis in Familial Transthyretin Amyloidosis.

Carr AS, Shah S, Choi D, Blake J, Phadke R, Gilbertson J, Whelan CJ, Wechalekar AD, Gillmore JD, Hawkins PN, Reilly MM.

J Neuromuscul Dis. 2019;6(2):267-270. doi: 10.3233/JND-180348.

PMID:
30856118
16.

The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis.

Rezk T, Gilbertson JA, Mangione PP, Rowczenio D, Rendell NB, Canetti D, Lachmann HJ, Wechalekar AD, Bass P, Hawkins PN, Bellotti V, Taylor GW, Gillmore JD.

J Pathol Clin Res. 2019 Jul;5(3):145-153. doi: 10.1002/cjp2.126. Epub 2019 Apr 2.

17.

Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance.

Kotecha T, Martinez-Naharro A, Yoowannakul S, Lambe T, Rezk T, Knight DS, Hawkins PN, Moon JC, Muthurangu V, Kellman P, Rakhit RD, Gillmore JD, Jeetley P, Davenport A, Fontana M.

Sci Rep. 2019 Feb 4;9(1):1388. doi: 10.1038/s41598-018-37845-4.

18.

A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis.

Sharpley FA, Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Fontana M, Hawkins PN, Wechalekar AD.

Blood Cancer J. 2019 Feb 4;9(2):16. doi: 10.1038/s41408-019-0180-1. No abstract available.

19.

A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement.

Manwani R, Page J, Lane T, Burniston M, Skillen A, Lachmann HJ, Gillmore JD, Fontana M, Whelan C, Hawkins PN, Wagner T, Wechalekar AD.

Amyloid. 2018 Dec;25(4):247-252. doi: 10.1080/13506129.2018.1552852. Epub 2019 Jan 19.

PMID:
30661419
20.

Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis.

Ross JC, Hutt DF, Burniston M, Page J, Steeden JA, Gillmore JD, Wechalekar AD, Hawkins PN, Fontana M.

Amyloid. 2018 Sep;25(3):203-210. doi: 10.1080/13506129.2018.1520087.

PMID:
30486686
21.

Oligonucleotide Drugs for Transthyretin Amyloidosis.

Adams D, Hawkins PN, Polydefkis M.

N Engl J Med. 2018 Nov 22;379(21):2086. doi: 10.1056/NEJMc1810994. No abstract available.

PMID:
30484624
22.

Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis.

Rezk T, Davenport A, Gan JJ, Lachmann HJ, Fontana M, Martinez-Naharro A, Sachchithanantham S, Guillotte C, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Hawkins PN, Gillmore JD.

Br J Haematol. 2019 Jun;185(5):977-980. doi: 10.1111/bjh.15675. Epub 2018 Nov 18. No abstract available.

PMID:
30450572
23.

Systemic immunoglobulin light chain amyloidosis.

Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA.

Nat Rev Dis Primers. 2018 Oct 25;4(1):38. doi: 10.1038/s41572-018-0034-3. Review.

PMID:
30361521
24.

Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience.

Rowczenio D, Quarta CC, Fontana M, Whelan CJ, Martinez-Naharro A, Trojer H, Baginska A, Ferguson SM, Gilbertson J, Rezk T, Sachchithanantham S, Mahmood S, Manwani R, Sharpley F, Wechalekar AD, Hawkins PN, Gillmore JD, Lachmann HJ.

Hum Mutat. 2019 Jan;40(1):90-96. doi: 10.1002/humu.23669. Epub 2018 Nov 1.

PMID:
30328212
25.

Reply: Amyloidosis in the Era of Mass Spectrometry-Based Proteomics.

Kotecha T, Martinez-Naharro A, Gillmore JD, Hawkins PN, Fontana M.

J Am Coll Cardiol. 2018 Oct 9;72(15):1881. doi: 10.1016/j.jacc.2018.08.1036. No abstract available.

26.

Plasminogen activation triggers transthyretin amyloidogenesis in vitro.

Mangione PP, Verona G, Corazza A, Marcoux J, Canetti D, Giorgetti S, Raimondi S, Stoppini M, Esposito M, Relini A, Canale C, Valli M, Marchese L, Faravelli G, Obici L, Hawkins PN, Taylor GW, Gillmore JD, Pepys MB, Bellotti V.

J Biol Chem. 2018 Sep 14;293(37):14192-14199. doi: 10.1074/jbc.RA118.003990. Epub 2018 Jul 17.

27.

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB.

N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153.

28.

Myocardial Edema and Prognosis in Amyloidosis.

Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, Knight DS, Zumbo G, Rosmini S, Maestrini V, Bulluck H, Rakhit RD, Wechalekar AD, Gilbertson J, Sheppard MN, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

J Am Coll Cardiol. 2018 Jun 26;71(25):2919-2931. doi: 10.1016/j.jacc.2018.03.536.

29.

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.

Manwani R, Sachchithanantham S, Mahmood S, Foard D, Sharpley F, Rezk T, Lane T, Quarta C, Fontana M, Lachmann HJ, Gillmore JD, Whelan C, Hawkins PN, Wechalekar AD.

Blood. 2018 Aug 16;132(7):761-764. doi: 10.1182/blood-2018-04-846493. Epub 2018 Jun 20. No abstract available.

PMID:
29925500
30.

Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.

Borthwick NJ, Lane T, Moyo N, Crook A, Shim JM, Baines I, Wee EG, Hawkins PN, Gillmore JD, Hanke T, Pepys MB.

PLoS One. 2018 May 17;13(5):e0197299. doi: 10.1371/journal.pone.0197299. eCollection 2018.

31.

Cardiac amyloidosis.

Martinez-Naharro A, Hawkins PN, Fontana M.

Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s30-s35. doi: 10.7861/clinmedicine.18-2-s30. Review.

32.

Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.

Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Kotecha T, Francis R, Rezk T, Quarta CC, Whelan CJ, Lachmann HJ, Wechalekar AD, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

JACC Cardiovasc Imaging. 2019 May;12(5):823-833. doi: 10.1016/j.jcmg.2018.02.016. Epub 2018 Apr 18.

PMID:
29680336
33.

Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds.

Wagner T, Page J, Burniston M, Skillen A, Ross JC, Manwani R, McCool D, Hawkins PN, Wechalekar AD.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1129-1138. doi: 10.1007/s00259-018-3995-2. Epub 2018 Apr 12.

34.

Native T1 and Extracellular Volume in Transthyretin Amyloidosis.

Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, Treibel TA, Whelan CJ, Knight DS, Kellman P, Ruberg FL, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

JACC Cardiovasc Imaging. 2019 May;12(5):810-819. doi: 10.1016/j.jcmg.2018.02.006. Epub 2018 Mar 14.

PMID:
29550324
35.

Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis.

Rezk T, Gilbertson JA, Rowczenio D, Bass P, Lachmann HJ, Wechalekar AD, Fontana M, Mahmood S, Sachchithanantham S, Whelan CJ, Wong J, Rendell N, Taylor GW, Hawkins PN, Gillmore JD.

Nephrol Dial Transplant. 2018 Feb 1;33(2):241-247. doi: 10.1093/ndt/gfw375.

PMID:
29401357
36.

Prevalence of Cardiac Amyloidosis in Patients Referred for Transcatheter Aortic Valve Replacement.

Scully PR, Treibel TA, Fontana M, Lloyd G, Mullen M, Pugliese F, Hartman N, Hawkins PN, Menezes LJ, Moon JC.

J Am Coll Cardiol. 2018 Jan 30;71(4):463-464. doi: 10.1016/j.jacc.2017.11.037. No abstract available.

37.

Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis.

Manwani R, Foard D, Mahmood S, Sachchithanantham S, Lane T, Quarta C, Youngstein T, Rezk T, Lachmann HJ, Gillmore JD, Fontana M, Whelan C, Hawkins PN, Wechalekar A.

Haematologica. 2018 Apr;103(4):e165-e168. doi: 10.3324/haematol.2017.178095. Epub 2018 Jan 5. No abstract available.

38.

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.

Richards DB, Cookson LM, Barton SV, Liefaard L, Lane T, Hutt DF, Ritter JM, Fontana M, Moon JC, Gillmore JD, Wechalekar A, Hawkins PN, Pepys MB.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaan3128. doi: 10.1126/scitranslmed.aan3128.

PMID:
29298867
39.

Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome.

Rowczenio DM, Pathak S, Arostegui JI, Mensa-Vilaro A, Omoyinmi E, Brogan P, Lipsker D, Scambler T, Owen R, Trojer H, Baginska A, Gillmore JD, Wechalekar AD, Lane T, Williams R, Youngstein T, Hawkins PN, Savic S, Lachmann HJ.

Blood. 2018 Mar 1;131(9):974-981. doi: 10.1182/blood-2017-10-810366. Epub 2017 Dec 28.

40.

Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism-UK Single Center Experience.

Rowczenio DM, Gomes SM, Aróstegui JI, Mensa-Vilaro A, Omoyinmi E, Trojer H, Baginska A, Baroja-Mazo A, Pelegrin P, Savic S, Lane T, Williams R, Brogan P, Lachmann HJ, Hawkins PN.

Front Immunol. 2017 Oct 31;8:1410. doi: 10.3389/fimmu.2017.01410. eCollection 2017.

41.

Prospective comparison of novel dark blood late gadolinium enhancement with conventional bright blood imaging for the detection of scar.

Francis R, Kellman P, Kotecha T, Baggiano A, Norrington K, Martinez-Naharro A, Nordin S, Knight DS, Rakhit RD, Lockie T, Hawkins PN, Moon JC, Hausenloy DJ, Xue H, Hansen MS, Fontana M.

J Cardiovasc Magn Reson. 2017 Nov 21;19(1):91. doi: 10.1186/s12968-017-0407-x.

42.

Extracellular volume with bolus-only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time.

Zumbo G, Barton SV, Thompson D, Sun M, Abdel-Gadir A, Treibel TA, Knight D, Martinez-Naharro A, Thirusha L, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

J Magn Reson Imaging. 2018 Jun;47(6):1677-1684. doi: 10.1002/jmri.25907. Epub 2017 Nov 21.

PMID:
29159946
43.

Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein.

Rowczenio D, Stensland M, de Souza GA, Strøm EH, Gilbertson JA, Taylor G, Rendell N, Minogue S, Efebera YA, Lachmann HJ, Wechalekar AD, Hawkins PN, Heimdal KR, Selvig K, Lægreid IK, Demoulin N, Aydin S, Gillmore JD, Wien TN.

Kidney Int Rep. 2016 Nov 19;2(3):461-469. doi: 10.1016/j.ekir.2016.11.005. eCollection 2017 May.

44.

A new staging system for cardiac transthyretin amyloidosis.

Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN.

Eur Heart J. 2018 Aug 7;39(30):2799-2806. doi: 10.1093/eurheartj/ehx589.

PMID:
29048471
45.

Misidentification of transthyretin and immunoglobulin variants by proteomics due to methyl lysine formation in formalin-fixed paraffin-embedded amyloid tissue.

Canetti D, Rendell NB, Di Vagno L, Gilbertson JA, Rowczenio D, Rezk T, Gillmore JD, Hawkins PN, Verona G, Mangione PP, Giorgetti S, Mauri P, Motta S, De Palma A, Bellotti V, Taylor GW.

Amyloid. 2017 Dec;24(4):233-241. doi: 10.1080/13506129.2017.1385452. Epub 2017 Oct 10.

PMID:
29016222
46.

Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.

Sachchithanantham S, Berlanga O, Alvi A, Mahmood SA, Lachmann HJ, Gillmore JD, Hawkins PN, Harding S, Wechalekar AD.

Br J Haematol. 2017 Nov;179(4):575-585. doi: 10.1111/bjh.14908. Epub 2017 Oct 8.

PMID:
28990174
47.

Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study.

Phillips EH, Nash S, Adedayo T, Whelan CJ, Fontana M, Mahmood S, Lachmann HJ, Gillmore JD, Smith P, Clifton-Hadley L, Hawkins PN, Wechalekar AD.

Amyloid. 2017 Dec;24(4):242-244. doi: 10.1080/13506129.2017.1385453. Epub 2017 Oct 6. No abstract available.

PMID:
28984490
48.

International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors.

Youngstein T, Hoffmann P, Gül A, Lane T, Williams R, Rowczenio DM, Ozdogan H, Ugurlu S, Ryan J, Harty L, Riminton S, Headley AP, Roesler J, Blank N, Kuemmerle-Deschner JB, Simon A, Woolf AS, Hawkins PN, Lachmann HJ.

Rheumatology (Oxford). 2017 Dec 1;56(12):2102-2108. doi: 10.1093/rheumatology/kex305.

49.

Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis.

Omoyinmi E, Standing A, Keylock A, Price-Kuehne F, Melo Gomes S, Rowczenio D, Nanthapisal S, Cullup T, Nyanhete R, Ashton E, Murphy C, Clarke M, Ahlfors H, Jenkins L, Gilmour K, Eleftheriou D, Lachmann HJ, Hawkins PN, Klein N, Brogan PA.

PLoS One. 2017 Jul 27;12(7):e0181874. doi: 10.1371/journal.pone.0181874. eCollection 2017.

50.

Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology.

Lane T, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ.

Amyloid. 2017 Sep;24(3):189-193. doi: 10.1080/13506129.2017.1352503. Epub 2017 Jul 26.

PMID:
28745926

Supplemental Content

Loading ...
Support Center